Angle secures $1.2 million follow-up contract from large-scale pharma company
- Company secures follow-up contract worth up to $1.2 million
- Ongoing discussions with multiple potential new customers
- First mover advantage in attractive liquid biopsy market
Biopsy technology company Angle (AGL:AIM) has won a follow-up contract with its first large scale pharma services customer it announced in April 2021, proving it can generate repeat business from large pharma ...